Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649172 | 0.86 | CYP3A4 (0.49) | GRIA1GRIA2GRIA3GRIA4CYP3A4 | |
| SCHEMBL5357066 | 0.72 | ALDH1A1 (0.49) | CYP3A4MAPTPOLBMAOBLMNA | |
| SCHEMBL2980594 | 0.71 | MAPT (0.51) | GRIA1GRIA2GRIA3GRIA4CYP3A4 | |
| SCHEMBL2072913 | 0.69 | GRIA1 (0.49) | GRIA1GRIA2GRIA3GRIA4CYP3A4 | |
| SCHEMBL207776 | 0.67 | AHR (0.42) | DAOTSHRALDH1A1 | |
| SCHEMBL207490 | 0.67 | AHR (0.42) | MAPTNOS1POLBLMNATSHR | |
| SCHEMBL207738 | 0.67 | AHR (0.42) | NOS1LMNACYP19A1 | |
| SCHEMBL1399575 | 0.67 | NOS1 (0.35) | NOS1 | |
| SCHEMBL29540314 | 0.67 | GABRA1 (0.70) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL155013 | 0.67 | GABRA1 (0.70) | GRIA1GRIA2GRIA3GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884886-B2 | Disulfide masked prodrug compositions and methods | MERCK SHARP & DOHME (US) | 2018-02-06 | — | — | US | claimed |
| WO-2009020771-A2 | RNAI AGENTS COMPRISING UNIVERSAL NUCLEOBASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | claimed |
| US-7323488-B2 | Chromogenic enzyme substrates | BURTON MICHAEL | 2008-01-29 | — | — | US | claimed |
| EP-1436411-B1 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2005-12-14 | — | — | EP | claimed |
| US-20050124556-A1 | Chromogenic enzyme substrates | BURTON MICHAEL (GB) | 2005-06-09 | — | — | US | claimed |
| EP-1436411-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | Burton, Michael (GB) | 2004-07-14 | — | — | EP | claimed |
| WO-2003035896-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2003-05-01 | — | — | WO | claimed |
| US-4831045-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | claimed |
| EP-0045165-B1 | RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-12 | — | — | EP | claimed |
| EP-0047109-B1 | RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | claimed |
| EP-0122109-A2 | Preparation of cyano- or aminoalkyl substituted aromatic amines | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-10-17 | — | — | EP | claimed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | claimed |
| CN-117402829-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-113943244-B | Sulfur-containing gamma, gamma-diindolylbutyramide compounds prepared by difunctional reactions | 温州大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-113943244-A | Sulfur-containing gamma, gamma-diindolyl butyramide compound prepared by double-functionalization reaction | 温州大学 | 2022-01-18 | — | — | CN | disclosed |
| US-4464382-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4446143-A | Rhodanine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
| EP-0045165-A1 | Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | NOP2, NOP58, FBL | GRIA1 3649/4885GRIA2 3573/4885GRIA3 2904/4885 |
| US-20050124556-A1 | Chromogenic enzyme substrates | DCXR, MGAM, IDE | GRIA1 3970/4885GRIA2 3816/4885GRIA3 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.